Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by AN2 Therapeutics, Inc.

< Previous 1 2 Next >

AN2 Therapeutics to Participate at Upcoming Investor Conferences

November 14, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

November 13, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

October 17, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 28, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

August 16, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

August 13, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

August 08, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

May 14, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

March 28, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

February 12, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

January 30, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

November 09, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Upcoming Investor Conferences

November 06, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

October 18, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

October 11, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

September 26, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

September 13, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

August 15, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

August 10, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 25, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

May 11, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

May 01, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

March 29, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Upcoming Investor Conferences

February 28, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

January 31, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 09, 2022

From AN2 Therapeutics, Inc.

Via GlobeNewswire

AN2 Therapeutics to Present at Upcoming Investor Conferences

November 02, 2022

From AN2 Therapeutics, Inc.

Via GlobeNewswire

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

October 19, 2022

From AN2 Therapeutics, Inc.

Via GlobeNewswire

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

October 06, 2022

From AN2 Therapeutics, Inc.

Via GlobeNewswire

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

September 29, 2022

From AN2 Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by AN2 Therapeutics, Inc.

Starting at /week.